Qualigen Therapeutics Inc...

NASDAQ: QLGN · Real-Time Price · USD
1.87
0.11 (6.01%)
At close: Aug 15, 2025, 3:42 PM

Qualigen Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a 5.2M 4.98M 5.65M
Cost of Revenue
n/a 5.21M 4.3M 4.33M
Gross Profit
n/a -4.5K 680.8K 1.32M
Operating Income
-5.76M -11.3M -17.94M -22.66M
Interest Income
128.79K n/a n/a 42.69K
Pretax Income
-6.15M -12.48M -21.3M -17.89M
Net Income
-6.16M -13.42M -21.03M -17.9M
Selling & General & Admin
4.2M 6.09M 11.79M 12.27M
Research & Development
1.2M 5.21M 6.84M 11.72M
Other Expenses
360K -5.21M 1.13K 5.45K
Operating Expenses
5.76M 6.1M 18.62M 23.98M
Interest Expense
908.94K 1.52M 34.4K n/a
Selling & Marketing Expenses
n/a -4.5K 950.42K 542.59K
Cost & Expenses
5.76M 11.3M 22.93M 28.32M
Income Tax Expense
6.33K -4.79K -265.07K 5.43K
Shares Outstanding (Basic)
361.59K 5.07M 3.84M 2.93M
Shares Outstanding (Diluted)
361.59K 5.07M 3.84M 2.93M
EPS (Basic)
-17.28 -2.46 -5.48 -6.1
EPS (Diluted)
-17.28 -2.46 -5.48 -6.1
EBITDA
-5.24M -11.3M -13.84M -22.66M
EBIT
-5.24M -11.3M -13.85M -22.66M
Depreciation & Amortization
n/a 4.5K 12.16K 322.06K